Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Hepion Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
HEPA
Nasdaq
8731
https://hepionpharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Hepion Pharmaceuticals Inc
Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell
- Mar 6th, 2024 1:30 pm
Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds
- Feb 16th, 2024 1:00 pm
Hepion Pharmaceuticals to Present at NASH-TAG 2024
- Jan 3rd, 2024 10:15 pm
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes
- Dec 7th, 2023 1:00 pm
Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit
- Nov 28th, 2023 9:15 pm
Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease
- Nov 13th, 2023 9:05 pm
Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat
- Nov 10th, 2023 1:50 pm
Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model
- Oct 25th, 2023 12:30 pm
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
- Sep 29th, 2023 12:00 pm
Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conference
- Sep 21st, 2023 8:05 pm
New Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals’ Rencofilstat in Cancer Screening Program
- Sep 21st, 2023 12:00 pm
Here's Why Hepion Pharmaceuticals (NASDAQ:HEPA) Must Use Its Cash Wisely
- Sep 19th, 2023 1:41 pm
Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver Cancer
- Sep 19th, 2023 1:00 pm
Insider Buying: Robert Foster Acquires 1,600 Shares of Hepion Pharmaceuticals Inc
- Sep 18th, 2023 3:01 pm
Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary Fibrosis
- Sep 14th, 2023 12:45 pm
Hepion Pharmaceuticals Announces Management Changes
- Sep 6th, 2023 8:30 pm
Hepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress™ 2023
- Jun 15th, 2023 8:45 pm
Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial of Rencofilstat
- Jun 15th, 2023 12:22 pm
Hepion Pharmaceuticals to Highlight AI-POWR™ at the 2023 CSPS Annual Symposium: The Next Frontiers in Pharmaceutical Sciences
- May 24th, 2023 8:45 pm
Hepion Pharmaceuticals’ Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers
- May 22nd, 2023 11:00 am
Scroll